ABCL · AbCellera Biologics Inc
United States · RS rating 98 · As of 2026-10-14
| Price | 12.37 USD |
|---|---|
| 1-day change | -1.9% |
| RS rating (overall / 1M / 3M / 12M) | 98 / 93 / 97 / 96 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 46 / 50 / 32 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -28.6% |
| Sales growth Q/Q | +400.9% |
| Distance from 52-week high | +16.5% |
| Market cap (USD) | $1.2B |